A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma

Novartis

Status and phase: Completed; Phase 2

Conditions: Asthma

Treatments: Drug: Placebo; Drug: FTY720

Study type: Interventional

Funder types: Industry

Identifiers

NCT00785083

CFTY720D2102

Details and patient eligibility

About

This study will evaluate the effect of FTY720 on the lung function of patients with moderate asthma

Enrollment: 36 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Forced Expiratory Volume in 1 second of at least 60%
• History of asthma for at least 6 months
• Current use of short-acting beta agonists, inhaled long-acting beta agonists and inhaled corticosteroids (up to a specified dose)

Exclusion criteria

• History of lung disease other than asthma
• Smokers
• Use of inhaled corticosteroid above specified dose
• Use of oral beta agonists or corticosteroids or other asthma medications
• Hypersensitivity to the drug
• Respiratory tract infections within 1 month of the study

Other protocol-defined inclusion/exclusion criteria may apply

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

36 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: FTY720

2

Placebo Comparator group

Treatment:

Drug: Placebo